MedPath

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public
Established
1989-01-01
Employees
5.4K
Market Cap
$123.9B
Website
http://www.vrtx.com
Clinical Trials
Related News

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Phase 1
Completed
Conditions
Pain
Interventions
First Posted Date
2023-05-09
Last Posted Date
2024-03-20
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
73
Registration Number
NCT05851157
Locations
πŸ‡ΊπŸ‡Έ

ICON Salt Lake City, Salt Lake City, Utah, United States

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Phase 3
Conditions
Cystic Fibrosis
Interventions
Drug: VNZ/TEZ/D-IVA
First Posted Date
2023-05-06
Last Posted Date
2025-05-07
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
174
Registration Number
NCT05844449
Locations
πŸ‡ΊπŸ‡Έ

Children's Hospital of Orange County, Orange, California, United States

πŸ‡ΊπŸ‡Έ

Stanford University, Palo Alto, California, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital of Colorado, Aurora, Colorado, United States

and more 29 locations

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

Phase 1
Completed
Conditions
Pain
Interventions
Drug: VX-548 Placebo
First Posted Date
2023-04-19
Last Posted Date
2024-03-20
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
72
Registration Number
NCT05818852
Locations
πŸ‡ΊπŸ‡Έ

ICON Lenexa, Lenexa, Kansas, United States

πŸ‡ΊπŸ‡Έ

ICON Salt Lake City, Salt Lake City, Utah, United States

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Phase 1
Active, not recruiting
Conditions
Type 1 Diabetes
Interventions
First Posted Date
2023-03-30
Last Posted Date
2025-06-06
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
7
Registration Number
NCT05791201
Locations
πŸ‡ΊπŸ‡Έ

UHealth Diabetes Research Institute, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

University of Chicago, Chicago, Illinois, United States

πŸ‡ΊπŸ‡Έ

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 13 locations

A Phase 1, First-in-human Study of VX-668

Phase 1
Completed
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
Drug: Placebo
First Posted Date
2023-02-14
Last Posted Date
2024-03-15
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
114
Registration Number
NCT05727800
Locations
πŸ‡ΊπŸ‡Έ

Celerion - Tempe, Tempe, Arizona, United States

πŸ‡ΊπŸ‡Έ

University of Florida, Gainesville, Florida, United States

πŸ‡ΊπŸ‡Έ

Central Florida Pulmonary Group, P.A., Orlando, Florida, United States

and more 2 locations

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Phase 1
Completed
Conditions
Pain
Interventions
First Posted Date
2023-01-30
Last Posted Date
2024-04-29
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
38
Registration Number
NCT05704556
Locations
πŸ‡ΊπŸ‡Έ

Infigo Clinical Research, DeLand, Florida, United States

πŸ‡ΊπŸ‡Έ

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

GCP Research, Saint Petersburg, Florida, United States

and more 4 locations

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Phase 1
Suspended
Conditions
Cystic Fibrosis
Interventions
Drug: VX-522 mRNA therapy
Drug: IVA
First Posted Date
2022-12-30
Last Posted Date
2025-07-02
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
36
Registration Number
NCT05668741
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Miller Children's Hospital / Long Beach Memorial, Long Beach, California, United States

πŸ‡ΊπŸ‡Έ

Stanford University Clinical and Translational Research Unit, Palo Alto, California, United States

and more 38 locations

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Phase 3
Completed
Conditions
Pain
Interventions
First Posted Date
2022-12-22
Last Posted Date
2025-07-01
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
258
Registration Number
NCT05661734
Locations
πŸ‡ΊπŸ‡Έ

Anaheim Clinical Trials, Anaheim, California, United States

πŸ‡ΊπŸ‡Έ

Trovare Clinical Research | Bakersfield, CA, Bakersfield, California, United States

πŸ‡ΊπŸ‡Έ

Mart Medical Research Group LLC, South Miami, Florida, United States

and more 10 locations

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Phase 2
Completed
Conditions
Diabetic Peripheral Neuropathy
Interventions
Drug: Placebo (matched to pregabalin)
Drug: Placebo (matched to VX-548)
First Posted Date
2022-12-21
Last Posted Date
2025-07-01
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
194
Registration Number
NCT05660538
Locations
πŸ‡ΊπŸ‡Έ

Pinnacle Research Group, LLC, Anniston, Alabama, United States

πŸ‡ΊπŸ‡Έ

Synexus Clinical Research US - Birmingham, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Synexus Clinical Research US - Phoenix West, Phoenix, Arizona, United States

and more 47 locations

A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

Phase 1
Completed
Conditions
Pain
Interventions
Drug: Placebo
First Posted Date
2022-12-16
Last Posted Date
2023-10-12
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
70
Registration Number
NCT05653323
Locations
πŸ‡¬πŸ‡§

MAC Clinical Research, Manchester, United Kingdom

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy